In Segment C, individuals will receive ABBV-744 and oral navitoclax. In Section D, contributors will receive ABBV-744 and ruxolitinib. Contributors will receive treatment right until disorder progression or even the members are unable to tolerate the study drugs. after which you can encourage H3K